Evidence map›Paper›PMID 39006423›Full record

ArticlemedRxiv : the preprint server for health sciences2024

Tumor Regression Following Engineered Polyomavirus-Specific T Cell Therapy in Immune Checkpoint Inhibitor-Refractory Merkel Cell Carcinoma.

Yuta Asano, Joshua Veatch, Megan McAfee, Jakob Bakhtiari, Bo Lee, Lauren Martin, Shihong Zhang, Francesco Mazziotta, Kelly G Paulson, Thomas M Schmitt and 17 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors.

Yuta AsanoFred Hutchinson Cancer Center, Seattle, WA, USA.
Joshua VeatchFred Hutchinson Cancer Center, Seattle, WA, USA.
Megan McAfeeFred Hutchinson Cancer Center, Seattle, WA, USA.
Jakob BakhtiariFred Hutchinson Cancer Center, Seattle, WA, USA.
Bo LeeFred Hutchinson Cancer Center, Seattle, WA, USA.
Lauren MartinFred Hutchinson Cancer Center, Seattle, WA, USA.
Shihong ZhangFred Hutchinson Cancer Center, Seattle, WA, USA.
Francesco MazziottaFred Hutchinson Cancer Center, Seattle, WA, USA.
Kelly G PaulsonSwedish Health Services, Edmonds, WA, USA.
Thomas M SchmittFred Hutchinson Cancer Center, Seattle, WA, USA.
Ariunnaa MunkbhatFred Hutchinson Cancer Center, Seattle, WA, USA.
Cecilia YoungFred Hutchinson Cancer Center, Seattle, WA, USA.
Brandon SeatonFred Hutchinson Cancer Center, Seattle, WA, USA.
Daniel HunterFred Hutchinson Cancer Center, Seattle, WA, USA.
Nick HorstFred Hutchinson Cancer Center, Seattle, WA, USA.
Marcus LindbergFred Hutchinson Cancer Center, Seattle, WA, USA.
Natalie MillerFred Hutchinson Cancer Center, Seattle, WA, USA.
Matt StoneFred Hutchinson Cancer Center, Seattle, WA, USA.
Jason BielasFred Hutchinson Cancer Center, Seattle, WA, USA.
David KoelleFred Hutchinson Cancer Center, Seattle, WA, USA.
Valentin VoilletFred Hutchinson Cancer Center, Seattle, WA, USA.
Raphael GottardoFred Hutchinson Cancer Center, Seattle, WA, USA.
Ted GooleyFred Hutchinson Cancer Center, Seattle, WA, USA.
Shannon OdaSeattle Children's Research Institute, Seattle, WA, USA.
Philip D GreenbergFred Hutchinson Cancer Center, Seattle, WA, USA.
Paul NghiemFred Hutchinson Cancer Center, Seattle, WA, USA.
Aude G ChapuisFred Hutchinson Cancer Center, Seattle, WA, USA.

Funding

Understand & overcome resistance to PD-1P01CA225517 · NCI · UNIVERSITY OF WASHINGTON · PI Cecilia C Yeung · 2019 to 2026
$22.7M
NCI NIH HHS P01 CA225517
6 · The paper itself

Abstract

Although immune check-point inhibitors (CPIs) revolutionized treatment of Merkel cell carcinoma (MCC), patients with CPI-refractory MCC lack effective therapy. More than 80% of MCC express T-antigens encoded by Merkel cell polyomavirus, which is an ideal target for T-cell receptor (TCR)-based immunotherapy. However, MCC often repress HLA expression, requiring additional strategies to reverse the downregulation for allowing T cells to recognize their targets. We identified TCR

Identifiers

PMID39006423
PMCPMC11245074

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.